{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:12:40Z","timestamp":1700262760056},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T00:00:00Z","timestamp":1140048000000},"content-version":"vor","delay-in-days":1083,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Musculoskeletal Care"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumour necrosis factor alpha (TNF\u03b1) has been identified in the pathogenesis of synovitis and joint destruction in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Therefore selected targeting of pathogenic elements of disease is possible (Chu et al., 1991). TNF\u03b1 is a pro\u2010inflammatory cytokine (mediator) and the over\u2010expression of mediators is considered to be responsible for the damage to articular cartilage in bones. Elevated levels of TNF\u03b1, correlating with disease activity, have been measured in the serum and synovial fluid of patients with rheumatic diseases and are therefore an ideal target for therapy (Mangge et al., 1995; Cope et al., 1992). The National Institute for Clinical Excellence (NICE) approved the use of two therapies; entanercept (Enbrel) and infliximab (Remicade) for use in patients with active RA in 2002 (NICE, 2002). Other biologic treatments including adalimumab (D2E7) and anakinra (Kineret) will also be available for use in the future. This paper explores the development of a service to provide these therapies to patients. Copyright \u00a9 2003 Whurr Publishers Ltd.<\/jats:p>","DOI":"10.1002\/msc.37","type":"journal-article","created":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T17:46:40Z","timestamp":1140112000000},"page":"34-43","source":"Crossref","is-referenced-by-count":3,"title":["Developing a service for biologic therapies: a personal experience"],"prefix":"10.1002","volume":"1","author":[{"given":"Margaret","family":"Somerville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,16]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1403"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.1780340908","article-title":"Localisation of tumour necrosis factor alpha in synovial tissues and at the cartilage\u2013pannus junction in patients with rheumatoid arthritis","volume":"34","author":"Chu CQ","year":"1991","journal-title":"Arthritis and Rheumatology"},{"issue":"9","key":"e_1_2_1_4_1","first-page":"2115","article-title":"Economic burden of rheumatoid arthritis","volume":"27","author":"Cooper N","year":"2000","journal-title":"A systematic review Journal of Rheumatology"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351008"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380209"},{"key":"e_1_2_1_7_1","unstructured":"NICE(2002).Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology Appraisal Guidance No 36. London: National Institute for Clinical Excellence."},{"key":"e_1_2_1_8_1","first-page":"393","article-title":"Clinical studies with an articular index for the assessments of joint tenderness in patients with rheumatoid arthritis","volume":"147","author":"Ritchie DM","year":"1968","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.8.735"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.7.793"}],"container-title":["Musculoskeletal Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsc.37","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msc.37","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T03:28:13Z","timestamp":1700191693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msc.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/msc.37"],"URL":"https:\/\/doi.org\/10.1002\/msc.37","archive":["Portico"],"relation":{},"ISSN":["1478-2189","1557-0681"],"issn-type":[{"value":"1478-2189","type":"print"},{"value":"1557-0681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}